➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Mallinckrodt
Merck
Baxter
Boehringer Ingelheim
Express Scripts

Last Updated: August 5, 2020

DrugPatentWatch Database Preview

Claims for Patent: 10,328,115

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,328,115
Title:Modulators of complement activity
Abstract: The present invention provides polypeptide modulators of complement activity, including cyclic polypeptide modulators. Also provided are methods of utilizing such modulators as therapeutics.
Inventor(s): Hoarty; Michelle Denise (Billerica, MA), Dhamnaskar; Ketki Ashok (Cambridge, MA), Elbaum; Daniel (Newton, MA), Josephson; Kristopher (San Carlos, CA), Larson; Kelley Cronin (Quincy, MA), Ma; Zhong (Lexington, MA), Nims; Nathan Ezekiel (Winchester, MA), Ricardo; Alonso (Cambridge, MA), Seyb; Kathleen (South Boston, MA), Tang; Guo-Qing (Acton, MA), Treco; Douglas A. (Arlington, MA), Wang; Zhaolin (Wellesley, MA), Ye; Ping (Lexington, MA), Zheng; Hong (New York, NY), Perlmutter; Sarah Jacqueline (Medford, MA)
Assignee: Ra Pharmaceuticals, Inc. (Cambridge, MA)
Application Number:15/905,158
Patent Claims:1. A method of reducing hemolysis in a subject, the method comprising administration of a C5 inhibitor to the subject, wherein: the C5 inhibitor is a polypeptide comprising an amino acid sequence corresponding to amino acid residues 9-12 of SEQ ID NO: 192, the C5 inhibitor is administered at a frequency of from about every 12 hours to about every 72 hours, and wherein hemolysis in subject plasma is reduced by at least 90% during the course of administration.

2. The method of claim 1, wherein the C5 inhibitor is administered daily.

3. The method of claim 1, wherein the C5 inhibitor is a polypeptide.

4. The method of claim 1, wherein the polypeptide comprises from about 10 to about 18 amino acids.

5. The method of claim 1, wherein the polypeptide comprises a cyclic loop.

6. The method of claim 1, wherein the polypeptide comprises an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 192.

7. The method of claim 6, wherein the polypeptide comprises a C-terminal lysine, wherein the C-terminal lysine is conjugated with a lipid.

8. The method of claim 7, wherein the polypeptide is conjugated with a hydrophilic polymer.

9. The method of claim 8, wherein the hydrophilic polymer comprises polyethylene glycol.

10. The method of claim 7, wherein the polypeptide comprises SEQ ID NO: 184.

11. The method of claim 7, wherein the polypeptide comprises SEQ ID NO: 194.

12. The method of claim 1, wherein the C5 inhibitor is administered at a dose of from about 0.01 mg/kg to about 20 mg/kg.

13. The method of claim 12, wherein the C5 inhibitor is administered at a dose of from about 0.3 mg/kg to about 3 mg/kg.

14. The method of claim 1, wherein the C5 inhibitor is administered at a dose sufficient to achieve C5 inhibitor plasma levels in the subject of from about 2 .mu.g/ml to about 20 .mu.g/ml.

15. The method of claim 14, wherein the C5 inhibitor is administered at a dose sufficient to achieve C5 inhibitor plasma levels in the subject of about 4 .mu.g/ml.

16. The method of claim 1, wherein the subject has a disease, disorder, or condition wherein C5 cleavage leads to progression of the disease, disorder, or condition.

17. The method of claim 16, wherein the disease, disorder, or condition comprises paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome, or myasthenia gravis.

18. The method of claim 1, wherein the subject has PNH.

19. The method of claim 1, wherein the subject has previously been treated with eculizumab.

20. The method of claim 19, wherein the subject is also receiving treatment with eculizumab.

21. The method of claim 19, wherein treatment with eculizumab is ineffective.

22. The method of claim 21, wherein the subject has an eculizumab-resistant C5 polymorphism.

Summary for Patent:   Start Trial

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
PCT/US2015/035473Jun 12, 2015

Details for Patent 10,328,115

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Alexion Pharm SOLIRIS eculizumab INJECTABLE; IV (INFUSION) 125166 001 2007-03-16   Start Trial Ra Pharmaceuticals, Inc. (Cambridge, MA) 2035-06-12 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Medtronic
McKesson
Express Scripts
Merck
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.